132 results about "Radiosensitizer" patented technology

The present invention relates to compounds of formula I:and pharmaceutically acceptable salts, stereoisomers or tautomers thereof which are inhibitors of poly (ADP-ribose) polymerase (PARP) and thus useful for the treatment of cancer, inflammatory diseases, reperfusion injuries, ischemic conditions, stroke, renal failure, cardiovascular diseases, vascular diseases other than cardiovascular diseases, diabetes, neurodegenerative diseases, retroviral infection, retinal damage or skin senescence and UV-induced skin damage, and as chemo- and / or radiosensitizers for cancer treatment.

The invention discloses an electronic radiation crosslinked polymeric material for 3D printing, a preparation method and a product thereof. The material includes following components, by weight, 100 parts of polymer resin, 0.5-5 parts of a radiosensitizer, 0.1-0.5 parts of an anti-oxidant agent, 1-20 parts of a powder and 1-10 parts of a pigment. With addition of the radiosensitizer, the polymer resin is subjected to a crosslinking reaction during a 3D printing process through electronic beam radiation to form a three-dimensional net structure so that a moulded material is significantly improved in heat resistant performance, chemical-corrosion resistant performance and mechanical strength. The polymer resin has a wider application prospect in 3D printing materials.

Herein is described Nanostructure Enhanced X-ray Therapy (NEXT), which uses nanomaterials as radiosensitizers to enhance electromagnetic radiation absorption in specific cells or tissues. The nanomaterial radiosensitizers emit Auger electrons and generate radicals in response to electromagnetic radiation, which can cause localized damage to DNA or other cellular structures such as membranes. The nanomaterial radiosensitizers contain moieties for specific targeting to molecules or structures in a cell or tissue, and can be functionalized for increased stability and solubility. The nanomaterial radiosensitizers can also be used as detection agents to help in early diagnosis of disease. Together with known techniques such as Computed Tomography or Computerized Axial Tomography (CT or CAT scan), these nanomaterial radiosensitizers could allow early diagnosis and treatment of diseases such as cancer and HIV.

The aquogel wound dressing containing radiosensitizer has aquogel comprising PVP, PVA, radiosensitizer, plasticizer, pH regulator, water, etc. The components of PVP, PVA, radiosensitizer, plasticizer and pH regulator are dissolved in water to prepare polymer aqua; the aqua is defoamed, poured onto non-woven fabric, frozen to cure and covered with stripping paper; and through cutting, radiating with Co-60 light source in the dosage of 15-65 kGy for chemical reaction and sterilization, the aquogel wound dressing is prepared. The aquogel wound dressing consists of three layers, including aquogel, non-woven fabric and stripping paper. It is suitable for use in protecting and treating wound of burns, scalds, ulcer, cutting, etc.

A method of sensitizing tumor cells to radiation thereapy, chemotherapy and immunomodulatory thereapy, comprising the step of exposing the tumor cell to an effective amount of at least one monoterpene or sesquiterpene and treating the tumor cell is disclosed.

A method of sensitizing tumor cells to radiation thereapy, chemotherapy and immunomodulatory thereapy, comprising the step of exposing the tumor cell to an effective amount of at least one monoterpene or sesquiterpene and treating the tumor cell is disclosed.

The invention relates to the use of designed β-sheet peptides together with radiation therapy for cancer treatment. The β-sheet peptides, which were designed using portions from several α-chemokines, exhibit activity as radiosensitizing agents, and have demonstrated synergism with radiation therapy for cancer treatment. The β-sheet peptides also exhibit activity as angiogenesis inhibitors.

The present invention relates to compounds of formula I:and pharmaceutically acceptable salts, stereoisomers or tautomers thereof which are inhibitors of poly (ADP-ribose) polymerase (PARP) and thus useful for the treatment of cancer, inflammatory diseases, reperfusion injuries, ischemic conditions, stroke, renal failure, cardiovascular diseases, vascular diseases other than cardiovascular diseases, diabetes, neurodegenerative diseases, retroviral infection, retinal damage or skin senescence and UV-induced skin damage, and as chemo- and / or radiosensitizers for cancer treatment.

The invention discloses a silicone rubber microporous foam material adopting a mixed cellular structure and a preparation method of the silicone rubber microporous foam material. The preparation method is characterized by comprising the following steps: mixing 100 parts of a silicone rubber base material, 15-45 parts of a reinforcing agent, 2-3 parts of a structure controlling agent, 60-125 parts of a pore-forming agent and 3-5 parts of a radiosensitizer, forming, radiating through gamma rays so as to enable the formed product to be crosslinked, wherein the radiation absorbed dose is 30-70 kGy, performing solventing-out section by section to form holes, and drying, so as to obtain the silicone rubber microporous foam material with excellent performance. According to the invention, the method that radiation crosslinking cooperates with solventing-out hole forming is adopted, so that crosslinking is uniform, control is convenient, energy conservation and environment friendliness are realized, the process is simple, reproducibility is good, and production efficiency is high; the prepared silicone rubber microporous foam material adopts the mixed cellular structure, and is excellent in comprehensive performance, small in hole, pure white in color, soft in texture, proper in crosslinking density and gel content, high in tensile strength and elongation at break and low in permanent tensile deformation and compression deformation.

Inhibitors of KIAA0175 are provided that reduce the expression or biological activities of KIAA0175, p53 and / or p21 in a mammalian cell. KIAA0175 inhibitors include anti-sense molecules, ribozymes, antibodies and antibody fragments, proteins and polypeptides as well as small molecules. KIAA0175 inhibitors find use in compositions and methods for decreasing KIAA0175, p53 and / or p21 gene expression as well as methods for increasing the chemo and / or radiosensitivity of mammalian cells, including tumor cells, methods for decreasing the side effects of cancer therapy and methods for treating neoplastic diseases.

Disclosed is a radiation sensitivity-enhancing composition in which a microRNA-21 inhibitor acts as an active ingredient. The microRNA-21 inhibitor is an antisense nucleic acid molecule binding complementarily to microRNA-21. The composition can be administered to a patient in conjunction with irradiation. The inhibitor can act as a radiosensitizer, enhancing the therapeutic effect of such irradiation on cancer high in microRNA-21 expression level, particularly, glioma.

The present invention relates to a method of treating cancer using PARP inhibitors as radio-sensitization agents of tumors. Specifically the present invention relates to a method of radio-sensitization of tumors using a compound of Formula (I)or a pharmaceutically acceptable salt form thereof. The present invention also relates to a pharmaceutical compositions of PARP inhibitors for radiosensitizing tumors.

Indole derivatives that are useful in the treatment of cancer as a chemotherapeutic agent or radiosensitizing agent.

Poly(ADP-ribose) polymerase-1 (PARP-1) is a central signaling enzyme in a cell nucleus. PARP-1 is a target for the development of radio and chemo sensitizing agents in cancer treatment as well as providing protection from stroke. An SH3 domain and an SH3 ligand domain have now been discovered on the PARP-1 protein. These domains are involved in PARP-1 activation. This discovery makes possible the use of bioinformatics tools for the design of new drugs and strategies for drug target selection, specifically targeting the PARP-1 enzyme.

The present invention covers radiosensitizers containing as an active ingredient halogenated derivatives of boronated porphyrins containing multiple carborane cages having the structurewhich selectively accumulate in neoplastic tissue within the irradiation volume and thus can be used in cancer therapies including, but not limited to, boron neutron-capture therapy and photodynamic therapy. The present invention also covers methods for using these radiosensitizers in tumor imaging and cancer treatment.

The invention discloses a carbon-based porous flexible composite wave-absorbing material and a preparation method thereof. The carbon-based porous flexible composite wave-absorbing material and the preparation method thereof are characterized in that pretreatment is conducted on one part of a carbon-based wave-absorbing agent, and then mixing molding is conducted on the treated carbon-based wave-absorbing agent, 0.2-0.4 part of a fluxing agent, 40-100 parts of silicone rubber, 10-30 parts of reinforcing agents, 0-5 parts of radiosensitizer and 0-3 parts of flame retardants; rubber materials molded through mixing are put into a mold, rolling is conducted on the rubber materials at 100-150 kg.cm<-2>, and a thin sheet with the thickness ranging from 0.5 mm to 5 mm is prepared; after plastic sealing is conducted on the thin sheet with the mold, the plastic-sealed thin sheet with the mold is put into a gamma-ray irradiation field or an electron beam accelerator to enable the total absorbed dose to be kept at 30-100 kGy, radiation crosslinking is conducted, after a plastic package and the mold are removed, edges are cut off, and the carbon-based porous flexible composite wave-absorbing material is obtained. According to the carbon-based porous flexible composite wave-absorbing material and the preparation method thereof, the technology is simple, complex chemical process control or professional auxiliary equipment is not needed, only simple equipment such as a double-roller mixing mill is needed, and the cost is lower; the prepared material is excellent in flexibility and wave-absorbing performance, the preparation process is easy and rapid to control, the repeatability is good, and energy conservation and environment protection are achieved.

Inhibitors of KIAA0175 are provided that reduce the expression or biological activities of KIAA0175, p53 and / or p21 in a mammalian cell. KIAA0175 inhibitors include anti-sense molecules, ribozymes, antibodies and antibody fragments, proteins and polypeptides as well as small molecules. KIAA0175 inhibitors find use in compositions and methods for decreasing KIAA0175, p53 and / or p21 gene expression as well as methods for increasing the chemo and / or radiosensitivity of mammalian cells, including tumor cells, methods for decreasing the side effects of cancer therapy and methods for treating neoplastic diseases.

In embodiments of the invention, a radiosensitizer or other agent is relatively uniformly accumulated in the cells of a tumor. An external monochromatic x-ray beam, which is tuned to a predetermined energy level associated with k-edge effects in the agent, is then directed to the tumor. The monochromatic x-ray beam activates the release of additional localized radiation from the agent. The additional radiation destroys the DNA of at least some tumor cells, making those tumor cells incapable of reproduction and repair. In embodiments of the invention, a single monochromatic x-ray beam source is used for both imaging and radiotherapy.

High energy phototherapeutic agents or radiosensitizer agents comprised of a halogenated xanthene, or other related agents that exhibit a preference for concentration in biologically sensitive structures in diseased tissue, and methods of treating and imaging using such radiosensitizer agents in such diseased tissue are described herein.

The present invention provides improved devices, methods, and kits for inhibiting restenosis and hyperplasia after intravascular intervention. In particular, the present invention provides controlled radiosensitizer delivery in combination with ionizing radiation to selected locations within a patient's vasculature to reduce and / or inhibit restenosis and hyperplasia rates with increased efficacy. In one embodiment, the combination radiation and radiosensitizer delivery catheter for inhibiting hyperplasia comprises a catheter body having a proximal end and distal end, an ionizing radiation source coupleable to the catheter body for applying a radiation dose to a body lumen, and means coupleable to the catheter body or the radiation source for releasing a radiosensitizer to the body lumen.

The present invention relates to a combination for the treatment of cancer wherein the combination exhibits a synergistic effect. The combination comprises radiation and at least one cyclin dependent kinase (CDK) inhibitor selected from the compounds of formula I or a pharmaceutically acceptable salt or a solvate thereof. The present invention also relates to a method for the treatment of cancer, which method comprises administering to a patient in need of such a treatment, a therapeutically effective amount of the combination. The present invention also relates to the use of a CDK inhibitor selected from the compounds of formula I as a radiosensitizer that enhances the efficacy of radiotherapy for the treatment of cancer, particularly head and neck cancer.

The invention relates to novel application of hsa-miR-185. The novel application is application of miR-185 in preparing products with function of enhancing the sensitivity of cells and / or tissues and / or organisms to radiation, or preparing products with function of treating and / or preventing tumors, or preparing products inhibiting signal channels activated or mediated by ATR genes, products inhibiting signal channels activated or mediated by ATR proteins, products inhibiting the ATR genes and / or products for inhibiting the ATR proteins. Experiments prove that: the miR-185 can directly inhibit tumor growth and enhance the sensitivity of cells to the radiation. Further experiments prove that: the functions of the miR-185 are realized by inhibiting the expression of the ATR genes in the cells. Therefore, the miR-185 is used for preparing medicines for treating tumors and radiosensitizers, and has important significance for treating the tumors and wide application prospect.

The present invention relates to a combination for the treatment of cancer wherein the combination exhibits a synergistic effect. The combination comprises radiation and at least one cyclin dependent kinase (CDK) inhibitor selected from the compounds of formula I or a pharmaceutically acceptable salt or a solvate thereof. The present invention also relates to a method for the treatment of cancer, which method comprises administering to a patient in need of such a treatment, a therapeutically effective amount of the combination. The present invention also relates to the use of a CDK inhibitor selected from the compounds of formula I as a radiosensitizer that enhances the efficacy of radiotherapy for the treatment of cancer, particularly head and neck cancer.

A combination of an anti-cancer agent and a metal radiosensitizer potentiates the radiotherapy of cancer. Said anti-cancer agent is preferably cisplatin while the metal radiosensitizer is preferably gold nanoparticles. Both the anti-cancer agent and the metal radiosensitizer bind to DNA and potentiate the radiotherapy of cancer by synergistically increases the amount of double strand breaks induced by the radiation. The anti-cancer agent and the metal radiosensitizer may be encapsulated in liposomes.

The invention relates to novel tricyclic 1,2,4-triazine-1-oxides and novel tricyclic 1,2,4-triazine-1,4-dioxides of formula Iand to related analogues, to their preparation, and to their use as hypoxia-selective drugs and radiosensitizers for cancer therapy, both alone or in combination with radiation and / or other anticancer drugs.

The invention relates to a cell nucleus targeted radiosensitizer and a preparation method thereof. The cell nucleus targeted radiosensitizer adopts a nucleus / shell cavity mesoporous silica structure, and comprises a mesoporous silica shell provided with a cavity, gadolinium-doped up-conversion fluorescence nano-particles positioned in the cavity of the mesoporous silica shell, a radiosensitization drug loaded in the cavity of the mesoporous silica shell, and a cell nucleus targeted ligand in covalent linkage with the surface of the mesoporous silica shell. According to the invention, the cell nucleus targeted radiosensitizer can realize the magnetic resonance / up-conversion luminescence dual-mode precise diagnosis and chemotherapy / radiotherapy efficient collaborative treatment for malignant tumor cell nucleuses, and is expected to achieve the optimal diagnosis and treatment efficiency.